Cargando…

Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo

The anticancer activity of Curaxin CBL0137, a DNA-binding small molecule with chromatin remodulating effect, has been demonstrated in different cancers. Herein, a comparative evaluation of CBL0137 activity was performed in respect to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fetisov, Timur I., Borunova, Anna A., Antipova, Alina S., Antoshina, Elena E., Trukhanova, Lubov S., Gorkova, Tatyana G., Zuevskaya, Svetlana N., Maslov, Alexei, Gurova, Katerina, Gudkov, Andrei, Lesovaya, Ekaterina A., Belitsky, Gennady A., Yakubovskaya, Marianna G., Kirsanov, Kirill I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856019/ https://www.ncbi.nlm.nih.gov/pubmed/36672738 http://dx.doi.org/10.3390/biomedicines11010230

Ejemplares similares

Insights into the Mechanism of Curaxin CBL0137 Epigenetic Activity: The Induction of DNA Demethylation and the Suppression of BET Family Proteins
por: Maksimova, Varvara, et al.
Publicado: (2023)

Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity
por: Kirsanov, Kirill, et al.
Publicado: (2022)

Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms
por: Jin, Ming-Zhu, et al.
Publicado: (2018)

Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers
por: Dallavalle, Sabrina, et al.
Publicado: (2021)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer
por: Burkhart, Catherine, et al.
Publicado: (2014)

Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats
por: Lesovaya, Ekaterina A., et al.
Publicado: (2015)

Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
por: Wang, Jiajia, et al.
Publicado: (2020)

EMBR-06. EFFECTIVE INHIBITION OF MYC-AMPLIFIFIED GROUP 3 MEDULLOBLASTOMA BY FACT-TARGETED CURAXIN DRUG CBL0137
por: Wang, Jiajia, et al.
Publicado: (2021)

MBRS-62. CURAXIN CBL0137 INHIBITS THE VIABILITY OF CANCEROUS CELLS IN PRE-CLINIC MODELS OF MYC-AMPLIFIED MEDULLOBLASTOMA
por: Wang, Jiajia, et al.
Publicado: (2020)

Current Approaches for Personalized Therapy of Soft Tissue Sarcomas
por: Kirsanov, Kirill I., et al.
Publicado: (2020)

Prevention of therapy-related malignances in cancer survivors
por: Belitsky, Gennady A., et al.
Publicado: (2019)

Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation
por: Jean, Maxime J., et al.
Publicado: (2017)

Effects of G-Quadruplex-Binding Plant Secondary Metabolites on c-MYC Expression
por: Zenkov, Roman G., et al.
Publicado: (2022)

Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
por: Singh, Baljinder, et al.
Publicado: (2023)

Molecular Mechanisms of Anticancer Activity of N-Glycosides of Indolocarbazoles LCS-1208 and LCS-1269
por: Zenkov, Roman G., et al.
Publicado: (2021)

A Brief Overview of the Paradoxical Role of Glucocorticoids in Breast Cancer
por: Zhidkova, Ekaterina M, et al.
Publicado: (2020)

Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins
por: Chang, Han-Wen, et al.
Publicado: (2018)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

The anti-cancer drugs curaxins target spatial genome organization
por: Kantidze, Omar L., et al.
Publicado: (2019)

CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer
por: Lindner, Daniel J., et al.
Publicado: (2020)

Analysis of Multiple Drug Resistance Mechanism in Different Types of Soft Tissue Sarcomas: Assessment of the Expression of ABC-Transporters, MVP, YB-1, and Analysis of Their Correlation with Chemosensitivity of Cancer Cells
por: Moiseeva, Natalia I., et al.
Publicado: (2022)

Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy
por: Fetisov, Timur I., et al.
Publicado: (2023)

Mechanism of curaxin-dependent nucleosome unfolding by FACT
por: Volokh, Olesya I., et al.
Publicado: (2022)

Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin
por: Kirilin, Evgeny M., et al.
Publicado: (2022)

Nutritional Sensor REDD1 in Cancer and Inflammation: Friend or Foe?
por: Zhidkova, Ekaterina M., et al.
Publicado: (2022)

HeLa TI cell-based assay as a new approach to screen for chemicals able to reactivate the expression of epigenetically silenced genes
por: Maksimova, Varvara, et al.
Publicado: (2021)

The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin’s lymphoma tumor growth by promoting apoptosis and autophagy
por: Lv, Yan, et al.
Publicado: (2023)

Cyclophilin A as a Pro-Inflammatory Factor Exhibits Embryotoxic and Teratogenic Effects during Fetal Organogenesis
por: Kalinina, Anastasiia, et al.
Publicado: (2023)

EHMTI-0137. Headache as an initial clinical symptom of carotid artery dissection
por: Slankamenac, P, et al.
Publicado: (2014)

The long winding road to the safer glucocorticoid receptor (GR) targeting therapies
por: Lesovaya, Ekaterina A., et al.
Publicado: (2022)

FACT is a sensor of DNA torsional stress in eukaryotic cells
por: Safina, Alfiya, et al.
Publicado: (2017)

Physiological and Functional Effects of Dominant Active TCRα Expression in Transgenic Mice
por: Kalinina, Anastasiia A., et al.
Publicado: (2023)

Minor grove binding ligands disrupt PARP-1 activation pathways
por: Kirsanov, Kirill I., et al.
Publicado: (2014)

Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency
por: Huemer, Martina, et al.
Publicado: (2016)

Combination of curaxin and tyrosine kinase inhibitors display enhanced killing of primitive Chronic Myeloid Leukaemia cells
por: Pearson, Stella, et al.
Publicado: (2022)

Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients
por: Pearson, Stella, et al.
Publicado: (2023)

TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells
por: Leonova, Katerina, et al.
Publicado: (2018)

REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids
por: Baida, Gleb, et al.
Publicado: (2015)

A novel CBL-B(flox/flox) mouse model allows tissue-selective fully conditional CBL/CBL-B double-knockout: CD4-Cre mediated CBL/CBL-B deletion occurs in both T-cells and hematopoietic stem cells
por: Goetz, Benjamin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g5njr0ofg2ca445t46po31d3ft